Your browser doesn't support javascript.
loading
Treatment of Relapsed and Refractory ALK-Positive Anaplastic Large Cell Lymphoma With ALK-Specific Tyrosine Kinase Inhibitor in Children: A Case Series.
Shen, Diying; Song, Hua; Zhang, Jingying; Liao, Chan; Wang, Yan; Fang, Meixin; Tang, Yongmin.
Afiliação
  • Shen D; Department of Hematology and Oncology, Pediatric Hematology-Oncology Center, Pediatric Leukemia Diagnosis and Therapeutic Technology Research Center of Zhejiang Province, The Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China.
J Pediatr Hematol Oncol ; 44(1): e1-e4, 2022 01 01.
Article em En | MEDLINE | ID: mdl-33661174
ABSTRACT
Relapsed and refractory ALK-positive anaplastic large cell lymphoma (ALCL) has a poor prognosis. In this report, we present 3 relapsed/refractory pediatric ALCL patients, 1 of these with central nervous system involvement. All 3 patients were treated with ALK inhibitor and achieved complete response. Both crizotinib and alectinib have shown significant activity in pediatric patients with refractory ALK-positive ALCL.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Piperidinas / Carbazóis / Linfoma Anaplásico de Células Grandes / Crizotinibe / Quinase do Linfoma Anaplásico / Proteínas de Neoplasias Tipo de estudo: Prognostic_studies Limite: Child / Female / Humans / Infant Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Piperidinas / Carbazóis / Linfoma Anaplásico de Células Grandes / Crizotinibe / Quinase do Linfoma Anaplásico / Proteínas de Neoplasias Tipo de estudo: Prognostic_studies Limite: Child / Female / Humans / Infant Idioma: En Ano de publicação: 2022 Tipo de documento: Article